Empirical antifungal therapy in selected patients with persistent fever and neutropenia (Q40492348)

21 September 2017

1 reference

title

Empirical antifungal therapy in selected patients with persistent fever and neutropenia (English)

1 reference

21 September 2017

José Miguel Cisneros

1

1 reference

21 September 2017

Ildefonso Espigado

2

1 reference

21 September 2017

Antonio Rivero

3

1 reference

21 September 2017

Fernando Lozano de León

4

1 reference

21 September 2017

Jorge Parra

5

1 reference

21 September 2017

Antonio Ramón Collado

6

1 reference

21 September 2017

José Manuel Lomas

7

1 reference

21 September 2017

Jerónimo Pachón

8

1 reference

21 September 2017

Sociedad Andaluza de Enfermedades Infecciosas

9

1 reference

21 September 2017

language of work or name

Spanish

0 references

publication date

1 December 2005

1 reference

Infectious Diseases and Clinical Microbiology

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

10

1 reference

21 September 2017

609-614

1 reference

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Numbers needed to treat (needlessly?)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Opportunistic CNS infection after bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Guidelines for treatment of candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Hepatic candidiasis in cancer patients: the evolving picture of the syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2805%2975041-2

7 January 2021

10.1016/S0213-005X(05)75041-2

Identifiers

DOI

1 reference

21 September 2017

1 reference